secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001193125-25-230898
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd announces FDA IND clearance for VYD2311; Phase 3 and Phase 2 trials to start year-end 2025
--------------------------------------------------------------------------------

- FDA cleared IND and aligned on pivotal clinical program for VYD2311, a vaccine-alternative monoclonal antibody to prevent COVID.
- DECLARATION Phase 3 trial (N=~2,000) will evaluate single and monthly IM doses vs placebo for 3-month prevention of symptomatic COVID.
- LIBERTY Phase 2 trial (N=~300) will compare safety/tolerability of VYD2311 vs mRNA vaccine and explore co-administration.
- Trials to begin year-end 2025 with top-line data anticipated mid-2026; funded by recent capital raise and commercial launch quantities ready.
- Details to be shared in public investor event later this month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525230898/0001193125-25-230898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525230898/ivvd-20251006.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer